- Home
- PSNL vs RGNX Comparison
PSNL vs RGNX Comparison
Compare PSNL & RGNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PSNL | RGNX |
|---|---|---|
| Founded | 2011 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 729.1M | 761.9M |
| IPO Year | 2019 | 2015 |
Fundamental Metrics
Financial Performance| Metric | PSNL | RGNX |
|---|---|---|
| Price | $6.72 | $8.57 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 6 | 8 |
| Target Price | $11.50 | ★ $28.75 |
| AVG Volume (30 Days) | ★ 1.3M | 810.3K |
| Earning Date | 05-18-2026 | 06-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 33.58 | 18.08 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $69,648,000.00 | $10,393,000.00 |
| Revenue This Year | $16.94 | $58.79 |
| Revenue Next Year | $36.58 | $29.74 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 126.48 |
| 52 Week Low | $2.83 | $5.04 |
| 52 Week High | $11.50 | $16.19 |
Technical Indicators
Market Signals| Indicator | PSNL | RGNX |
|---|---|---|
| Relative Strength Index (RSI) | 34.61 | 40.83 |
| Support Level | $4.31 | $7.83 |
| Resistance Level | $6.94 | $9.28 |
| Average True Range (ATR) | 0.71 | 0.64 |
| MACD | -0.19 | 0.20 |
| Stochastic Oscillator | 5.95 | 23.57 |
Price Performance
Historical ComparisonAbout PSNL Personalis Inc.
Personalis Inc is a provider of genomic sequencing and analytics solutions to support the development of personalized cancer vaccines and other next-generation cancer immunotherapies. It has one segment, the sale of sequencing and data analysis services. Its products include ImmunoID NeXT, NeXT Personal, NeXT Dx Test, and other pharma research solutions.
About RGNX REGENXBIO Inc.
Regenxbio Inc is a biotechnology company. Its main activity is the development and commercialization of recombinant adeno associated virus gene therapy to correct an underlying genetic defect. The diseases that the Regenxbio platform targets are metabolic (homozygous familial hypercholesterolemia), neurodegenerative conditions (mucopolysaccharidosis), and retinal diseases (wet age-related macular degeneration, X-linked retinitis pigmentosa). The company derives the majority of its revenue from the United States.